LXB improves functional outcomes in patients with idiopathic hypersomnia
LXB improved all measures of function and work productivity among patients with idiopathic hypersomnia, according to findings presented at the American Neurological Association Annual Meeting.The treatment (calcium, magnesium, potassium and sodium oxybates; Jazz Pharmaceuticals Inc.), also referred to as lower-sodium oxybate (LXB) and Xywav, has the same active moiety at the same concentration as